Not provided
Not provided
Not provided
Not provided
Not provided
Cryogenesis company stopped supplying mesenchymal cells
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Randomized clinical study involving 44 patients, evaluating the effect of mesenchymal cells on rotator cuff repair. The primary outcome will be post-operative MRI tendon integrity and secondary outcomes clinical assessment by the UCLA and American Shoulder and Elbow Surgeons (ASES) scales and pain by visual analog scale (VAS).
Rotator cuff tendinopathy is the main cause of shoulder pain and tear of these tendons affects 20% of the population. Although arthroscopic repair leads to satisfactory clinical results, the retear rates varies from 4 to 94%. The main cause of failure after rotator cuff repair is not related to the material used, but to the tissue deficiency and the healing process between the tendon and the bone. After the intervention, the rotator cuff does not restore its original histological characteristics and its fixation occurs through scar tissue with lower biomechanical resistance. There are few clinical studies on the use of mesenchymal cells in rotator cuff repair,, with good results.
The investigators will perform a randomized clinical study involving 44 patients, evaluating the effect of mesenchymal cells on rotator cuff repair. The primary outcome will be post-operative MRI tendon integrity and secondary outcomes clinical assessment by the UCLA and American Shoulder and Elbow Surgeons (ASES) scales and pain by visual analog scale (VAS).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Mesenchymal stem cell group | Experimental | rotator cuff repair stem cells |
|
| Control group | Active Comparator | rotator cuff repair |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Mesenchymal stem cell | Biological | Mesenchymal stem cells applies at the end of rotator cuff repair in de active group |
|
| Measure | Description | Time Frame |
|---|---|---|
| MRI integrity | Sugaya classification | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES) | minimum 0 points, maximum 100 points. Higher values are considered best outcomes. | 6, 12 and 24-months |
| University at California at Los Angeles Shouder Rating Scale (UCLA) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| EDUARDO ANGELI MALAVOLTA A Malavolta, PhD | MD, PhD, Associate Professor | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Universidade de São Paulo | São Paulo | São Paulo | 05403-010 | Brazil |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000070636 | Rotator Cuff Injuries |
| D013708 | Tendon Injuries |
| ID | Term |
|---|---|
| D012421 | Rupture |
| D014947 | Wounds and Injuries |
| D000070599 | Shoulder Injuries |
Not provided
Not provided
Randomized controlled trial
Not provided
Not provided
Surgeon and patients not blinded
| Rotator cuff repair | Procedure | Rotator cuff repair |
|
minimum 3 points, maximum 35 points. Higher values are considered best outcomes. |
| 6, 12 and 24-months |
| Visual Analog Scale for Pain (VAS) | miminum 0 points, maximum 10 points. Higher values are considered worst outcomes. | 6, 12 and 24-months |